Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Non-small Cell Lung Cancer Metastatic 1Lung Neoplasms 1

Interventions

Carboplatin 347pembrolizumab 322Pemetrexed 246Cisplatin 218Paclitaxel 147Nivolumab 138durvalumab 133osimertinib 112Docetaxel 111atezolizumab 109Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 76Radiosurgery 72Gemcitabine 71Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 44Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
dacomitinib × Thoracic × 1 year × Clear all
NCT06486142 2026-05-14

ERIS

Region Skane

Phase 3 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04721106 2026-02-10

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

Pfizer

Completed
188 enrolled
Thoracic

Lung Neoplasms

NCT03810807 2025-12-23

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
22 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04504071 2025-09-08

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Shanghai Chest Hospital

Phase 2 Active not recruiting
30 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡